background
human
metapneumoviru
hmpv
caus
upper
lower
respiratori
tract
infect
uri
lri
respect
healthi
immunocompromis
patient
howev
clinic
burden
patient
cancer
remain
unknown
method
retrospect
studi
laboratoryconfirm
hmpv
infect
treat
author
institut
april
may
clinic
characterist
risk
factor
progress
lri
treatment
outcom
patient
cancer
determin
result
total
hmpv
infect
identifi
patient
hematolog
malign
hm
hematopoiet
cell
transplant
hct
recipi
patient
solid
tumor
patient
communityacquir
infect
present
uri
develop
lri
present
lri
progress
uri
lri
multivari
analysi
underli
hm
adjust
odd
ratio
aor
confid
interv
ci
p
nosocomi
infect
aor
ci
p
hypoxia
oxygen
satur
present
aor
ci
p
identifi
independ
factor
associ
lri
allcaus
mortal
day
hmpv
diagnosi
low
patient
lri
mortal
rate
day
diagnosi
wherea
patient
uri
mortal
rate
conclus
hmpv
infect
patient
cancer
may
caus
signific
morbid
especi
underli
hm
may
develop
lri
despit
high
morbid
lack
direct
antivir
therapi
hmpv
infect
mortal
day
infect
remain
low
studi
popul
human
metapneumoviru
hmpv
envelop
nonseg
neg
rnaparamyxovirida
viru
discov
netherland
report
adult
children
communityacquir
pneumonia
viru
affect
age
group
upper
respiratori
infect
uri
lower
respiratori
tract
infect
lri
howev
sever
diseas
describ
young
children
older
adult
diagnosi
hmpv
respiratori
specimen
depend
molecular
assay
ie
revers
transcriptasepolymeras
chain
reaction
sensit
older
method
like
direct
fluoresc
antibodi
viral
cultur
serolog
adopt
new
molecular
assay
filmarray
respiratori
panel
biofir
diagnost
llc
salt
lake
citi
utah
enhanc
diagnosi
patient
respiratori
viral
infect
secondari
hmpv
respiratori
virus
respiratori
specimenshmpv
infect
immunocompromis
host
describ
small
case
seri
patient
cancer
hmpv
incid
similar
immunocompet
popul
approxim
hmpvassoci
lri
report
mani
patient
cancer
children
undergo
hematopoiet
cell
transplant
hct
yet
hmpvassoci
mortal
remain
low
unless
bronchoalveolar
lavag
bal
find
posit
viru
studi
limit
small
sampl
size
inadequ
power
determin
risk
factor
outcom
hmpv
infect
patient
cancer
associ
mortal
morbid
although
support
measur
may
place
hmpv
treatment
remain
challeng
vitro
activ
drug
choic
ribavirin
inhibit
hmpv
replic
addit
intraven
immunoglobulin
ivig
without
ribavirin
use
patient
hmpv
infect
lack
systemat
evalu
efficaci
ecil
european
confer
infect
leukemia
address
communityacquir
respiratori
virus
includ
hmpv
howev
therapi
lack
systemat
evalu
larg
retrospect
studi
object
determin
clinic
characterist
outcom
hmpv
infect
patient
cancer
immunocompromis
attempt
character
risk
factor
associ
develop
hmpvassoci
lri
hmpvassoci
mortal
allcaus
mortal
identifi
patient
specif
underli
malign
higher
risk
outcom
may
suitabl
target
antivir
therapi
studi
conduct
univers
texa
md
anderson
cancer
center
houston
tex
infect
control
databas
search
identifi
patient
laboratoryconfirm
hmpv
infect
april
may
biofir
filmarray
respiratori
panel
institut
use
diagnos
respiratori
viral
infect
includ
hmpv
institut
review
board
approv
protocol
waiver
inform
consent
grant
review
patient
medic
record
collect
follow
data
demograph
includ
age
sex
race
smoke
histori
cancer
type
cancer
statu
complet
remiss
activ
diseas
time
infect
hct
recipi
review
underli
cancer
type
transplant
matchedrel
donor
matchedunrel
donor
haploident
mismatch
autolog
sourc
bone
marrow
cord
peripher
date
hct
receipt
myeloabl
versu
nonmyeloabl
condit
regimen
type
immunosuppress
therapi
use
time
engraft
histori
type
graftversushostdiseas
acut
chronic
grade
organ
involv
cytomegaloviru
serostatu
hmpv
infect
episod
includ
coinfect
within
day
hmpv
episod
date
symptom
onset
type
infect
time
present
communityacquir
vs
nosocomi
acquisit
infect
site
present
uri
vs
lri
absolut
neutrophil
count
anc
absolut
lymphocyt
count
alc
cglobulin
level
avail
day
present
system
steroid
use
dose
record
within
day
infect
diagnosi
also
collect
data
outcom
therapi
includ
whether
patient
requir
hospit
length
stay
admit
intens
care
unit
admiss
onset
later
use
mechan
ventil
receipt
ribavirin
oral
vs
aerosol
form
ivig
date
caus
death
oxygen
satur
present
record
well
lowest
oxygen
satur
infect
type
oxygen
supplement
nasal
cannula
ventimask
facemask
vapotherm
bilevel
posit
airway
pressur
definit
hmpv
case
defin
studi
situat
patient
cancer
develop
acut
symptomat
respiratori
ill
posit
nasal
wash
result
andor
bal
find
indic
hmpv
communityacquir
case
occur
patient
develop
symptom
outpati
andor
hospit
within
first
day
admiss
symptomat
hmpv
infect
develop
day
hospit
consid
nosocomi
acquir
uri
defin
develop
rhinorrhea
nasal
sinu
congest
otiti
media
pharyng
cough
short
breath
hypoxemia
infiltr
chest
radiograph
imag
patient
posit
hmpv
test
result
nasal
wash
lri
defin
new
worsen
pulmonari
infiltr
observ
chest
radiograph
andor
hmpv
detect
lower
respiratori
specimen
endotrach
tube
aspir
sputum
bal
neutropenia
defin
anc
lymphopenia
defin
alc
allcaus
mortal
assess
within
day
day
hmpv
diagnosi
attribut
hmpv
patient
persist
progress
hmpv
lri
respiratori
failur
time
death
evalu
patient
characterist
use
descript
statist
categor
variabl
compar
use
chisquar
test
fisher
exact
test
continu
variabl
compar
use
student
test
wilcoxon
ranksum
test
multivari
logist
regress
use
identifi
risk
factor
associ
lri
result
report
adjust
odd
ratio
aor
confid
interv
ci
secondari
model
restrict
patient
present
uri
n
also
construct
identifi
risk
factor
progress
uri
lri
probabl
progress
uri
lri
cancer
group
hematolog
malign
hm
hct
solid
tumor
compar
use
kaplanmei
failur
curv
p
valu
consid
statist
signific
statist
analys
perform
sing
stata
softwar
version
statacorp
colleg
station
tex
april
may
laboratoryconfirm
hmpv
infect
identifi
patient
cancer
patient
solid
tumor
hct
recipi
remiss
hm
patient
relaps
hm
hct
includ
hm
group
patient
characterist
depict
tabl
median
age
year
rang
year
men
patient
nonhispan
white
n
never
smoke
n
among
patient
hm
posthct
statu
multipl
myeloma
common
underli
malign
major
patient
communityacquir
infect
detect
throughout
year
peak
april
may
fig
occur
uri
overal
lri
rate
patient
hm
highest
rate
lri
allcaus
mortal
rate
day
infect
diagnosi
respect
patient
characterist
associ
lri
depict
tabl
patient
lri
like
uri
hm
aor
ci
p
nosocomi
acquir
hmpv
aor
ci
p
hypoxia
oxygen
satur
present
aor
ci
p
logist
model
restrict
patient
present
uri
underli
hm
signific
predictor
progress
lri
aor
ci
p
nosocomi
acquir
infect
aor
ci
p
kaplanmei
failur
curv
indic
significantli
higher
incid
lri
hm
group
versu
solid
tumor
hct
group
p
fig
age
sex
smoke
statu
immunodefici
statu
base
anc
alc
valu
steroid
use
presenc
pulmonari
copathogen
hmpv
diagnosi
significantli
affect
progress
lri
cohort
among
patient
lri
underw
bal
hmpv
detect
escherichia
coli
detect
patient
pathogen
detect
remain
patient
copathogen
recov
bal
sampl
patient
posit
lri
hmpv
includ
cytomegaloviru
n
e
coli
n
methicillinresist
staphylococcu
aureu
n
methicillinsensit
aureu
n
parainfluenza
viru
piv
n
respiratori
syncyti
viru
rsv
n
coronaviru
n
arthrographi
n
twelv
patient
die
within
median
day
rang
day
hmpv
diagnosi
mortal
rate
similar
cancer
group
patient
probabl
hmpvattribut
death
relaps
refractori
hm
matchedunrel
donor
hct
recipi
progress
respiratori
failur
within
day
hmpv
diagnosi
rang
day
patient
hmpvassoci
death
pulmonari
coinfect
stenotrophomona
maltophilia
aspergillu
terreu
remain
patient
die
cancer
relaps
n
caus
n
median
day
rang
day
five
patient
receiv
ribavirin
therapi
uri
stage
lri
stage
patient
receiv
ivig
uri
stage
lri
stage
patient
die
respiratori
failur
receiv
ivig
receiv
aerosol
ribavirin
ivig
lri
stage
wherea
other
receiv
antivir
therapi
pulmonari
function
test
infect
perform
hct
recipi
allogen
hct
autolog
hct
recipi
averag
day
rang
day
hmpv
diagnosi
evid
airflow
declin
defin
drop
least
forc
expiratori
volum
prehct
postinfect
observ
patient
includ
underw
matchedrel
donor
hct
underw
matchedunrel
donor
hct
underw
autolog
hct
median
delta
drop
rang
within
median
day
rang
day
hmpv
infect
five
patient
lri
howev
patient
surviv
subgroup
hct
recipi
cglobulin
level
check
time
present
significantli
higher
level
cglobulin
observ
patient
uri
mgdl
versu
lri
mgdl
p
retrospect
studi
hmpv
infect
patient
cancer
report
high
incid
lri
low
overal
mortal
infect
risk
factor
associ
lri
underli
hm
nosocomi
acquir
infect
hypoxia
age
categor
interv
present
patient
hm
like
progress
uri
lri
hct
recipi
patient
solid
tumor
patient
die
within
day
hmpv
diagnosi
develop
lri
mortal
rate
patient
lri
vs
patient
uri
overal
lri
rate
observ
patient
cancer
find
higher
measur
previou
studi
report
lri
rate
patient
cancer
hmpv
diagnosi
incid
hmpv
lri
consist
report
respiratori
virus
among
hct
recipi
patient
hm
sever
risk
factor
associ
lri
identifi
hypoxia
time
diagnosi
substanti
risk
factor
multivari
analysi
hypoxia
supplement
oxygen
requir
diagnosi
associ
higher
rate
lri
death
patient
cancer
rsv
piv
influenza
oxygen
use
may
surrog
marker
extent
lung
injuri
may
lead
poor
outcom
interest
note
underli
diagnosi
hm
significantli
increas
risk
lri
current
limit
data
hmpv
infect
patient
hm
impact
howev
underli
hm
report
signific
risk
factor
progress
lri
patient
pivassoci
respiratori
infect
patient
hm
might
high
level
immunosuppress
caus
activ
chemotherapi
time
hmpv
infect
underli
relaps
refractori
diseas
subsequ
prolong
cytopenia
compar
engraft
hct
recipi
remiss
nosocomi
acquisit
hmpv
associ
significantli
higher
risk
hmpvassoci
lri
substanti
number
nosocomi
hmpv
infect
also
describ
previou
hmpv
studi
patient
hm
respiratori
virus
transmit
either
asymptomat
symptomat
patient
famili
member
health
care
worker
highlight
import
infectioncontrol
measur
nosocomi
infect
associ
higher
morbid
rate
studi
popul
neutropenia
andor
lymphopenia
describ
major
risk
factor
lri
death
associ
respiratori
virus
observ
studi
studi
examin
patient
cancer
hmpv
may
explain
find
patient
risk
factor
similarli
risk
factor
progress
lri
death
ie
older
age
smoke
histori
steroid
use
report
respiratori
virus
observ
popul
hmpv
infect
overal
mortal
rate
day
day
consist
previou
smaller
case
seri
patient
cancer
also
rate
hmpvassoci
death
evalu
respiratori
viral
infect
patient
cancer
ie
rsv
piv
lower
incid
mortal
associ
hmpv
infect
patient
cancer
suggest
differ
viral
factor
genotyp
viral
fit
virul
rather
host
factor
studi
warrant
ribavirin
mainli
use
treat
rsv
infect
hct
recipi
demonstr
vitro
activ
hmpv
direct
antivir
effect
mous
model
reduc
viral
replic
case
report
use
ribavirin
associ
good
outcom
sever
hmpv
infect
patient
cancer
studi
mortal
rate
remain
low
despit
lack
ribavirin
use
patient
particularli
lri
subgroup
analysi
hct
recipi
cglobulin
level
check
time
present
observ
significantli
higher
level
cglobulin
patient
uri
lri
level
cglobulin
much
lower
patient
chronic
lymphocyt
leukemia
histori
infect
chronic
lymphocyt
leukemia
histori
infect
suggest
higher
cglobulin
level
protect
wors
outcom
standard
ivig
administr
inhibit
hmpv
replic
vitro
hypothes
ivig
administr
may
benefici
hct
recipi
prevent
progress
hmpv
uri
lri
howev
associ
ivig
administr
lri
prevent
could
demonstr
studi
need
systemat
determin
futur
trial
identifi
signific
risk
factor
age
smoke
statu
level
immunodefici
anc
alc
type
condit
regimen
cytomegaloviru
serostatu
donor
recipi
graftversushostdiseas
time
engraft
hct
cell
sourc
hct
recipi
exposur
steroid
studi
receipt
mgkg
steroid
within
week
diagnosi
signific
risk
factor
identifi
progress
lri
accord
multivari
regress
analys
hct
recipi
retrospect
studi
mani
limit
includ
lack
hmpv
quantif
respiratori
secret
indic
diseas
sever
observ
hmpv
studi
popul
higher
viral
load
associ
increas
risk
lri
hospit
sever
studi
suggest
sever
diseas
symptom
manifest
vari
hmpv
genotyp
inform
avail
cohort
patient
cancer
burden
hmpv
infect
similar
burden
associ
respiratori
viral
infect
howev
mortal
rate
hmpv
infect
lower
associ
relat
virus
rsv
patient
hm
nosocomi
infect
hypoxia
present
close
monitor
risk
progress
lri
hmpv
may
acquir
nosocomi
lead
wors
outcom
high
morbid
strict
adher
infectioncontrol
measur
univers
hand
hygien
underscor
signific
cglobulin
level
role
ivig
prevent
hmpvassoci
lri
andor
mortal
determin
futur
studi
especi
among
hct
recipi
patient
hm
studi
support
part
nation
institut
healthnat
cancer
institut
award
use
cancer
center
support
grant
resourc
author
made
disclosur
fira
el
chaer
conceptu
design
studi
clinic
research
data
collect
help
data
acquisit
writinginiti
draft
writingrevis
final
review
respons
overal
content
guarantor
dimpi
p
shah
conceptu
design
studi
perform
statist
analys
writinginiti
draft
writingrevis
final
review
respons
overal
content
guarantor
joumana
kmeid
clinic
research
data
collect
writingrevis
final
review
ella
j
arizaheredia
help
data
acquisit
writingrevis
final
review
chitra
hose
help
data
acquisit
writingrevis
final
review
victor
e
mulanovich
writingrevis
final
review
roy
f
chemali
conceptu
design
studi
help
data
acquisit
writinginiti
draft
writingrevis
final
review
respons
overal
content
guarantor
